Investors may want to keep an eye on gene editing stocks heading into December.
There are two strong catalysts that could send related stocks even higher.
In just days, the US FDA could approve the CRSP treatment, making it the first gene-editing treatment for sickle cell disease on the market. Not only could that boost CRSP stock, but it could also set off a firestorm of interest in all-things gene editing.
The catalyst date for potential approval is December 8.
That’s not all.
On December 11, its competitor – Editas Medicine (EDIT) will share clinical data updates from the RUBY trial for severe sickle cell disease (SCD) and the EdiTHAL trial for transfusion-dependent beta thalassemia (TDT) in a Company-sponsored webinar and in a poster at the American Society of Hematology (ASH) Annual Meeting on Monday, December 11.”
While investors can always jump into EDIT and CRSP ahead of the decisions, another way to potentially profit is with an ETF, such as the ARK Genomic Revolution ETF (ARKG).
With an expense ratio of 0.75, the fund invests in stocks that benefit from genomics. Some of its top holdings include Exact Sciences (EXAS), CRISPR Therapeutics (CRSP), Schrodinger (SDGR), and Beam Therapeutics (BEAM).
There’s also the Global X Genomics and Biotechnology ETF (GNOM).
With an expense ratio of 0.50%, the ETF invests in companies that potentially stand to benefit from further advances in the field of genomic science. Some of its top holdings include CRISPR Therapeutics, Intellia Therapeutics, 10X Genomics, and Beam Therapeutics to name a few.